Russia: Production of Sterile Pharmaceuticals Bilfinger Delivers a Pharmaceutical Production Plant to Nova Medica
Bilfinger Industrietechnik Salzburg, a subsidiary of the Bilfinger Group, has been awarded a contract by the Russian pharma company Nova Medica for the design and construction of three solution-preparation lines for the production of sterile, pharmaceutical dosage forms. This is the first contract the company has secured in Russia.
Salzburg/Austria — The production facility to be constructed will turn out chemical and biochemical products, emulsions, and cytostatic agents under aseptic conditions. The scope of delivery will include 15 mixing and buffer tanks with a capacity of up to 1,000 liters, as well as several isolators.
The engineering company will be responsible for the engineering, mechanical and electrical fabrication, automation and re-assembly work, as well as for on-site commissioning and acceptance testing (SAT). The fully automated production plant will be planned and built on the basis of an aseptic design and will meet the cGMP standards as well as the strictest international and Russian standards of quality. It will be controlled by means of a modern software system. The construction project is to be completed in 2020 and the first medicinal products are scheduled to be greenlit for industrial production in 2023.
The production plant will be installed in a newly built pharmaceutical complex within the Vorsino industrial park in the Kaluga region, 190 km southwest of Moscow.